10,081 Shares in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Bought by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. acquired a new stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,081 shares of the company’s stock, valued at approximately $32,000.

A number of other institutional investors also recently bought and sold shares of CKPT. Geode Capital Management LLC boosted its holdings in shares of Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after buying an additional 124,787 shares in the last quarter. HB Wealth Management LLC lifted its holdings in shares of Checkpoint Therapeutics by 96.9% during the fourth quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after purchasing an additional 75,560 shares during the period. PVG Asset Management Corp boosted its holdings in shares of Checkpoint Therapeutics by 9.2% in the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after acquiring an additional 12,676 shares in the last quarter. State Street Corp increased its position in Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after purchasing an additional 23,000 shares during the period. Finally, Walleye Capital LLC purchased a new position in Checkpoint Therapeutics in the third quarter worth $148,000. 22.00% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CKPT shares. HC Wainwright reiterated a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday. D. Boral Capital reiterated a “buy” rating and set a $4.80 price target (down from $9.00) on shares of Checkpoint Therapeutics in a report on Monday. Finally, Lake Street Capital reiterated a “hold” rating and issued a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday.

Checkpoint Therapeutics Trading Down 0.5 %

CKPT opened at $3.98 on Thursday. The company has a fifty day simple moving average of $3.13 and a 200 day simple moving average of $3.10. The firm has a market cap of $194.36 million, a price-to-earnings ratio of -2.16 and a beta of 1.41. Checkpoint Therapeutics, Inc. has a twelve month low of $1.38 and a twelve month high of $4.50.

Insider Buying and Selling

In other news, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.15, for a total transaction of $32,542.65. Following the sale, the chief executive officer now directly owns 3,775,019 shares in the company, valued at approximately $11,891,309.85. This represents a 0.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William Garrett Gray sold 268,432 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the transaction, the chief financial officer now directly owns 1,032,754 shares of the company’s stock, valued at approximately $4,141,343.54. This trade represents a 20.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 582,336 shares of company stock worth $2,156,801. 2.10% of the stock is currently owned by corporate insiders.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.